BC Extra | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin  Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer....
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Innovations | Jul 13, 2017
Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
BC Week In Review | Dec 7, 2015
Company News

Helsinn, Eisai sales and marketing update

Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo netupitant /palonosetron as an option to prevent acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy regimens. Helsinn...
BC Week In Review | Sep 28, 2015
Company News

Helsinn, Chugai sales and marketing update

Chugai launched Akynzeo netupitant /palonosetron in the U.K. to prevent chemotherapy-induced nausea and vomiting (CINV). The cost of the fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and 0.5...
BC Week In Review | Jun 15, 2015
Clinical News

Akynzeo netupitant/palonosetron regulatory update

The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy. The product is a fixed-dose combination of 300 mg...
BC Week In Review | Mar 30, 2015
Clinical News

Akynzeo netupitant/palonosetron regulatory update

EMA’s CHMP recommended approval of Akynzeo netupitant/palonosetron (NEPA) from Helsinn to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or with moderately emetogenic cancer chemotherapy. The product is a...
BC Week In Review | Feb 23, 2015
Company News

Helsinn, Stendhal deal

Helsinn granted Stendhal exclusive rights to commercialize netupitant /palonosetron ( NEPA ) in Colombia, Ecuador, Mexico, Peru, Venezuela and undisclosed Central American countries. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1)...
BC Week In Review | Feb 16, 2015
Company News

Helsinn, Mundipharma deal

Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA . The fixed-dose combination of 300 mg netupitant , a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist, is...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
Items per page:
1 - 10 of 30